



Targeting Interleukin-6 in Inflammatory Diseases






Dysregulated interleukin-6 (IL-6) production & disease onset¹



IL-6 targeted therapies²



IL-6 inhibitors in the management of rheumatoid arthritis



Abbreviations
ACR-EULAR, American College of Rheumatology-The European League Against Rheumatism; AOSD, adult-onset Still's disease; CDAI, clinical disease activity index; CRS, cytokine release syndrome; DAS28, disease activity score using 28 joint counts; IV, intravenous; Treg, regulatory T cell; GCA, giant cell arteritis; pJIA, polyarticular juvenile idiopathic arthritis; QxW, dosing every x weeks; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor κB (NF-κB) ligand; s.c., subcutaneously; SDAI, simplified disease activity index; sJIA, systemic juvenile idiopathic arthritis; VEGF, vascular endothelial growth factor.

References
1. Tanaka et al. Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. 2. Choy et al. Nat Rev Rheumatol. 2020 Jun;16(6):335-345. 3. Alekha et al. Ann Rheum Dis. 2022 Aug 11;annrheumdis-2022-222784. 4. Kastrati et al. RMD Open. 2022 Sep;8(2):e002359.

This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.

